Category: precision medicine
Population-based cancer surveillance provides a quantitative measurement of cancer occurrence in the United States and globally. Core activities of surveillance include measuring cancer incidence and characterizing each cancer with regard to histopathology, stage, and treatment in the context of survival. Cancer surveillance has been crucial in informing policy and practice, as well as clinical and Read More >Posted on by
In a 2013 blog post, we asked the question: “When should we all have our genomes sequenced?” At that time, we concluded that the time is not right and that “if we want to use whole genome sequencing in the course of regular preventive care and health promotion, research should be conducted to evaluate its Read More >Posted on by
In August 2016, we published a point-counterpoint viewpoint asking a crucial question that has been on the minds of researchers, health care providers and the public health community: “will precision medicine improve population health?” We understood that we were tackling “the elephant in the room” and hoped for reactions to this viewpoint. We were pleased Read More >Posted on by
In this week’s Journal of American Medical Association, we published a point-counterpoint commentary on the impact of precision medicine on population health. Announcement of the news of the US precision medicine initiative has been met with a range of responses from enthusiasm to skepticism about potential benefits, limitations and return on investment. In considering the Read More >Posted on by
The Shift From Personalized Medicine to Precision Medicine and Precision Public Health: Words Matter!
Advances in genomics and other ‘omic’ technologies have ushered in a new era variably called “personalized” or “precision” medicine, which takes into account individual genetic and other sources of variability in disease treatment and prevention. In the past decade, we have seen a significant growth in interest and usage of the terms personalized and precision Read More >Posted on by
We explore briefly the expanding role of population sciences in the implementation of the NIH Precision Medicine Initiative (PMI). The initiative includes a major component on cancer precision treatment, and a large scale cohort study program to generate knowledge applicable to all areas of health and disease, including cancer risk factors and outcomes. Genomics is Read More >Posted on by
It has been a year since the announcement of the new US Precision Medicine Initiative. As new funding is awarded to investigators across the country, the pace of assembling the cohort of a million or more individuals will accelerate. This cohort will link information from genomic, behavioral, social, environmental, and health outcomes to discover and Read More >Posted on by
In 2015, the United States launched the precision medicine initiative that includes a cancer component and a national cohort research study of one million or more people. While much of this initiative will take years to develop outputs for use in health care, a public health perspective is crucial to ensure the initiative’s success in Read More >Posted on by
From the State of the Union through a number of NIH-led workshops to a report from the Advisory Committee to the NIH Director [PDF 1.05 MB], and the recently launched NIH funding announcements, the Precision Medicine Initiative has the potential to reimagine how we can use information on our biology, our environment, our experiences, our Read More >Posted on by
Genomic discoveries to clinical applications: Are we reaching an inflection point toward precision medicine?
Each year at the annual American Society of Human Genetics (ASHG) meeting I follow certain rituals. During the first “poster session”, I quickly peruse all of the vendor booths on the floor to assess something of the overall flavor of the commercial space’s focus. During the next two poster sessions I cruise all of the Read More >Posted on by
- Content source: